Central nervous system disease
Participant must not have a known uncontrolled malignancy of the central nervous system.
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Known or suspected brain or central nervous system metastases, irrespective of prior treatment
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Known or suspected brain or central nervous system metastases, irrespective of prior treatment
Active central nervous system metastases
Known central nervous system mass lesion
Central nervous system metastases
History of seizure disorders or unstable central nervous system metastases
Known central nervous system metastases
Central nervous system malignancy
Metastatic disease to the central nervous system
Patients with known central nervous system metastases, including lymphomatous meningitis
Central nervous system metastases, including lymphomatous meningitis
Without clinical signs of active central nervous system disease
Known central nervous system or visceral metastases
Known central nervous system malignancy. Note: Central nervous system imaging is only required in subjects with suspected central nervous system malignancy.
Active central nervous system metastases and/or leptomeningeal disease
Uncontrolled central nervous system metastases
Patients/subjects with suspected or known central nervous system metastases unless adequately treated
Patients with active visceral, central nervous system, or any bone metastases melanoma (stage IVMb or IVMc)
Patient has known active central nervous system metastases.
Must not have suspected or known central nervous system metastases unless adequately treated
Active central nervous system malignancy
Rapidly progressive, clinically unstable central nervous system hematological malignancy. Note: Central nervous system evaluation is only required in subjects with known or suspected central nervous system malignancy.
Persons with uncontrolled central nervous system malignancy
Active central nervous system malignancy
History of central nervous system disease (e.g., seizures) unrelated to cancer unless adequately controlled by medication
Active meningeal or central nervous system disease
Presence of any central nervous system tumor that has not been stable for at least  weeks off corticosteroids.
Subjects must not have a history of neurodegenerative or central nervous system movement disorder
AND (by central assessment) either:
Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis
Previous radiotherapy for central nervous system metastases
Patients with known malignant disease of the central nervous system.
Any history of disease involving the central nervous system (Part ). Known active disease involving the central nervous system (Part ).
Active central nervous system tumor or metastases
Active central nervous system malignancy
Active central nervous system malignancy
Patients may have active malignancy outside the central nervous system
Known central nervous system brain metastases
Active central nervous system malignancy
Known central nervous system metastases
Uncontrolled central nervous system metastases
Central nervous system disease as evidence by clinical symptomatology
Subjects with known central nervous system disease
Patient must have no prior history or current clinically apparent central nervous system metastases
Known central nervous system metastases or central nervous system as the only source of disease
Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least  weeks, have no overt evidence of neurological deficit and are ?  weeks from completion of brain irradiation.
Active central nervous system disease.
Known central nervous system metastases or central nervous system as the only source of disease
Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS rearrangement
Uncontrolled central nervous system metastases
Participants with known central nervous system disease
Has known active central nervous system metastases
Known brain or central nervous system metastases or history of uncontrolled seizures.
Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral corticosteroids
Subjects with active central nervous system metastases
Known or suspected central nervous system metastases
Have confirmed presence of central nervous system metastases
Patients with known central nervous system metastases.
Patients with brain metastases must have at least one site of measurable disease outside of the central nervous system
Central nervous system metastases
Brain metastases, meningeal tumours or other metastases in the central nervous system
Current central nervous systemic disease
Presence of known central nervous system or brain metastases
Subjects with active cancer that has spread to the central nervous system
Asymptomatic, central nervous system metastases are permitted
Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis
Clinical or radiographic evidence of central nervous system metastases or significant cardiovascular disease
Central nervous system function defined as not severely somnolent or comatose (central cortical neurotoxicity scale < grade )
History of demyelinating disease or inflammatory disease of the central nervous system or the peripheral nervous system
Patients with primary central nervous system tumors or brain metastases.
Active or history of central nervous system metastases.
Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)
History or clinically suspicious for cancer-related Central Nervous System disease
Patient have uncontrolled brain metastases or central nervous system disease.
Patients may have active malignancy outside the central nervous system
Active central nervous system metastases
Known central nervous system malignancy.
Known central nervous system metastases
Known or suspected brain or central nervous system metastases
Known central nervous system metastases
Central nervous system injury or severe neurological impairment
Central nervous system metastases
History of central nervous system hemorrhage
Known presence of central nervous system metastases
Central nervous system metastases
Any history or signs of central nervous system metastases;
In the investigator's judgment, focal neurologic deficit as a result of metastases in the brain, spine, or other central nervous system disorders.
Severe central nervous system, pulmonary, or renal disease not related to the participant's cancer.
Patient has no worsening central nervous system symptoms; and
Known central nervous system disease (e.g., Alzheimer's disease).
Patients with central nervous system disease
Active central nervous system tumors or metastases
Radiographic evidence of central nervous system metastases that are not well controlled with local therapy (irradiation or surgery)
History or presence of known central nervous system metastases
Subjects with known central nervous system metastases.
Uncontrolled central nervous system metastases
Central nervous system tumors are allowed
Metastatic disease to the central nervous system
Active MM involving the central nervous system.
Active central nervous system lesions
Known central nervous system metastases or central nervous system as the only source of disease
Known or suspected brain or other central nervous system metastases
Active central nervous system malignancy
Known metastases to the central nervous system
Subjects with known central nervous system disease
Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study.
MM involving the central nervous system.
